FACT #1 : This stock is under heavy short action for the last couple of months, with daily short volume being in the 60-70% range on a regular basis.
FACT #2 : The CEO has gone on record saying there are no fundamental changes in the company that would explain the current heavy decline in pps.
FACT #3 : Institutional investors continue to accumulate.
FACT #4 : Initiation of Phase II remains set for Q3.
FACT #5 : Company can submit the required clinical trial information up to 21 days after enrollment of the first participant - anyone thinking Phase II wont start in Q3 because it's not on CliniclTrials.gov is misinformed. https://clinicaltrials.gov/ct2/manage-recs/fdaaa#WhenDoINeedToRegister
Imo, Ocata is now heavily oversold, with short action continuing. Things are heating up!
I'm following the BIG money and will continue to accumulate at these oversold levels.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.